Grass Pollen Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 3 and 2 respectively.
Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Grass Pollen Allergy - Overview
- Grass Pollen Allergy - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Grass Pollen Allergy - Therapeutics Assessment
- Assessment by Route of Administration
- Assessment by Molecule Type
- Grass Pollen Allergy - Companies Involved in Therapeutics Development
- ALK-Abello A/S
- Allergy Therapeutics Plc
- Biomay AG
- HAL Allergy BV
For more information about this report visit https://www.researchandmarkets.com/research/h9bwmk/grass_pollen